Stock Forecast

  MaxCyte, Inc. ( MXCT) Stock. Should you Buy or Sell?    $ 6.38

-0.10 (-1.59 %)



MaxCyte, Inc. Analysis

Updated on 10-09-2022
Symbol MXCT
Price $6.38
Beta 1.262
Volume Avg. $460.61 thousand
Market Cap $628.14 M
52 Week Range $3.36 - $16.28


MaxCyte, Inc. opened the day at $6.38 which is -1.59 % on yesterday's close. MaxCyte, Inc. has a 52 week high of $16.28 and 52 week low of $3.36, which is a difference of $12.92. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $628.14 M and total net profit is $33894100 which means the company is trading at 18.53 times profit to market capitalization. Theoretically, if you were to buy MaxCyte, Inc. for $628.14 M, it would take 15 years to get your money back. MaxCyte, Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




MaxCyte, Inc. Stock Forecast - Is MaxCyte, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -32.547
Dividend Yiel 0.000
Net Profit Margin -0.479


Valuing MaxCyte, Inc.


Price Book Value Ratio 2.516 Price To Book Ratio 2.516
Price To Sales Ratio 15.598 Price Earnings Ratio -32.547


How liquid is MaxCyte, Inc.


Current Ratio 14.239
Quick Ratio 13.740


Debt


Debt Ratio 0.112 Debt Equity Ratio 0.127
Long Term Debt To Capitalization 0.052 Total Debt To Capitalization 0.053



Latest news about MaxCyte, Inc.


MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.

Date : 07/09/2022

MaxCyte lifts guidance again as cell therapy demand continues to grow

MaxCyte Inc (AIM:MXCT) has again raised its full-year outlook as it continued to enjoy strong growth in the cell therapy market. Revenue came in at US$9.6mln for the second quarter of 2022, up 35% year-on-year, with the core business growing 45% and drug discovery up 4%.

Date : 11/08/2022

MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q2 2022 Results - Earnings Call Transcript

MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Sean Menarguez - Director of Investor Relations Doug Doerfler - Founder, President & Chief Executive Officer Ron Holtz - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Operator Good day, and thank you for standing by, and welcome to MaxCyte Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Date : 10/08/2022

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 10/08/2022

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the second quarter of 2022 after the U.S. market close on Wednesday, August 10th, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Date : 15/07/2022





About MaxCyte, Inc.


CEO :
Sector : Healthcare
Industry : Medical Devices

Website : https://maxcyte.com

Exchange : NASDAQ Global Select

Description :

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.


My Newsletter

Sign Up For Updates & Newsletters